|
LRCH3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.76014758324072E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.57200047318429E-10 |
| Normal-vs-Stage2 |
3.93550000366005E-08 |
| Normal-vs-Stage3 |
4.28980184707939E-11 |
| Normal-vs-Stage4 |
2.12190043313853E-10 |
| Stage1-vs-Stage2 |
2.482800E-01 |
| Stage1-vs-Stage3 |
1.523030E-01 |
| Stage1-vs-Stage4 |
2.644300E-02 |
| Stage2-vs-Stage3 |
9.155000E-01 |
| Stage2-vs-Stage4 |
5.518200E-01 |
| Stage3-vs-Stage4 |
4.239600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.24678045665405E-12 |
| Normal-vs-AfricanAmerican |
1.120910E-03 |
| Normal-vs-Asian |
1.97700000004186E-06 |
| Caucasian-vs-AfricanAmerican |
2.348200E-01 |
| Caucasian-vs-Asian |
5.067000E-01 |
| AfricanAmerican-vs-Asian |
5.219600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.95732319241415E-13 |
| Normal-vs-Female |
1.7924994821783E-11 |
| Male-vs-Female |
5.499800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.40110000268479E-08 |
| Normal-vs-Age(41-60Yrs) |
1.82149850758151E-11 |
| Normal-vs-Age(61-80Yrs) |
8.74500472036743E-11 |
| Normal-vs-Age(81-100Yrs) |
8.756100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.274000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.432100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.019600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.391800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.890200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.656000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.961800E-02 |
| Classical-VS-Follicular |
4.079200E-03 |
| Classical-VS-Other |
9.451700E-02 |
| Classical-VS-Normal |
2.10779949050277E-10 |
| Tall-VS-Follicular |
9.102800E-01 |
| Tall-VS-Other |
4.677600E-01 |
| Tall-VS-Normal |
3.35500000003819E-07 |
| Follicular-VS-Other |
5.184800E-01 |
| Follicular-VS-Normal |
4.60029792037631E-11 |
| Other-VS-Normal |
5.763300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25222054947471E-12 |
| Normal-vs-N1 |
7.69019958823947E-10 |
| N0-vs-N1 |
3.147800E-01 |
|
|
